# Navigating the Evolving SLE/Lupus Nephritis Landscape: Keys to Successful Product Launches

**Authors:**

**Sawyer May** Insights Director, Rheumatology. Spherix Global Insights Exton, PA 19341

**Ryan Rex** Insights Director II, Rheumatology. Spherix Global Insights Exton, PA 19341

**Lynn Price** Franchise Head, Rheumatology. Spherix Global Insights Exton, PA 19341

***Senior Author:*** Michelle Petri, MD Professor of Medicine at the Johns Hopkins University School of Medicine Director, Hopkins Lupus Center

## Executive Summary

Systemic lupus erythematosus (SLE) and lupus nephritis (LN) represent some of the most complex autoimmune conditions facing healthcare providers and pharmaceutical companies today. Despite advances in understanding disease pathways and developing targeted therapies, the commercial landscape remains challenging, characterized by lengthy diagnostic journeys, evolving treatment paradigms, and complex patient presentations.

This white paper examines the current state of the SLE/LN marketplace, identifying key trends and success factors that drive product performance. Drawing on extensive research across fifteen different drug launches between 2020 and 2021, including belimumab and anifrolumab in lupus, as well as upadacitinib in atopic dermatitis (AD), secukinumab in non-radiographic axial spondyloarthritis (nr-axSpa), ustekinumab in ulcerative colitis (UC), efgartigimod alfa in generalized myasthenia gravis (gMG), risankizumab in psoriatic arthritis (PsA), budesonide in immunoglobulin A nephropathy (IgAN), ixekizumab in non-radiographic axial spondyloarthritis (nr-axSpa), ruxolitinib in atopic dermatitis (AD), guselkumab in psoriatic arthritis (PsA), and ozanimod in ulcerative colitis (UC), this analysis provides insights into successful launch strategies. These products were selected because they have now been on the market for three years, allowing for ample time to evaluate launch performance.

The data reveal that products achieve approximately 30% of their prescriber projected peak market share by year three on average. Standout performers like belimumab reached 64% of its projected peak share by year three in LN.[1,2] These findings offer valuable perspectives for stakeholders navigating this dynamic therapeutic landscape.

## Understanding the SLE/LN Landscape

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect virtually any organ system, with manifestations ranging from mild skin and joint involvement to life-threatening renal and neurological complications. Lupus nephritis (LN), which occurs in approximately 40% of SLE patients, represents one of the most severe complications of lupus and a significant cause of morbidity and mortality.[1,3]

SLE is the most common form of lupus, accounting for about 70% of overall lupus cases.[2,4] While the exact cause remains unknown, genetic and environmental factors are believed to play significant roles in disease development.[5,6,7] In SLE patients, the immune system mistakenly targets the body's own tissues, commonly involving the skin and joints, though the specific tissues affected can vary widely from patient to patient. The disease follows a relapsing-remitting course in most patients, with periods of flares alternating with relative quiescence.[8]

The diagnosis of SLE relies on established classification criteria, with the 2019 EULAR/ACR criteria being the current standard. These criteria require a positive antinuclear antibody (ANA) titer as an entry criterion, followed by weighted criteria across clinical and immunological domains, with a score of ≥10 points indicating SLE classification.[9]

The therapeutic landscape for SLE/LN has historically been characterized by limited options, with treatment primarily consisting of corticosteroids, antimalarials, and immunosuppressants such as mycophenolate mofetil (MMF). The past decade has witnessed significant evolution, with new targeted therapies entering the market and changing treatment paradigms.

Understanding this evolving landscape requires specialized knowledge that goes beyond surface-level market research. The lupus market represents a unique intersection of complex biology, evolving clinical practice, and significant unmet need. Success in this space demands a nuanced understanding of both the science and the market dynamics at play.

### Mortality and Comorbidities in SLE

SLE disease and its treatments contribute significantly to mortality rates. Research indicates that after an initial decrease between 1968 and 1975, SLE mortality increased annually for twenty-four years, followed by a sustained decrease for fourteen years starting in 1999.[10,11] While mortality among SLE patients has improved significantly over recent decades, these improved survival rates are not consistent across all ethnic and racial groups.[12,13] Current data suggests that with proper treatment, 80-90% of people with lupus can expect to live a normal lifespan, though this varies based on disease severity and organ involvement.[14]

The leading causes of mortality in SLE have evolved over time. Until the 1980s, vascular events were the primary cause of death; however, this shifted in the 1990s when infections became the leading cause. In the twenty-first century, depression and organ damage have also been directly linked with increased mortality in lupus.[15,16]

Several factors influence mortality risk in SLE patients. The use of certain medications, including rituximab, cyclophosphamide, and high-dose glucocorticoids like prednisone, has been associated with increased mortality. Conversely, antimalarials such as hydroxychloroquine have been shown to improve survival.[15,16] Risk increases substantially with the presence of renal disease, cardiovascular disease, and certain infections. Men with SLE are more likely than women to develop lupus nephritis, which is associated with increased mortality.[7,10]

SLE patients frequently present with multiple comorbidities, including hypertension, anxiety, arthralgia, depression, and anemia. Cardiovascular disease, malignancy, and infections contribute to mortality in these patients.[16]

## The Changing Face of Lupus Treatment

### From Broad Immunosuppression to Targeted Therapies

The treatment paradigm for SLE/LN has undergone significant transformation in recent years. Traditional approaches centered around broad immunosuppression with steroids and immunosuppressants like mycophenolate mofetil and cyclophosphamide. These treatments come with substantial toxicity and side effect profiles that limit their long-term use and had an unacceptably low one-year “complete renal response” rate of about 20%.[17,18]

The introduction of belimumab, an anti-B lymphocyte stimulator (BLyS) monoclonal antibody, marked a turning point, offering the first FDA-approved biologic specifically for SLE in 2011,[19] followed by approval for LN in 2020.[1,17] Voclosporin, a calcineurin inhibitor (CNI), was approved for LN in January 2021, only a month after belimumab’s LN approval.[20,21] Subsequently, anifrolumab received approval in 2021, providing another targeted approach to addressing the type I interferon pathway implicated in lupus pathogenesis.[22]

These targeted approaches are gradually reshaping treatment patterns. Rheumatologists and nephrologists are becoming increasingly comfortable with biologic therapies in lupus as they seek options that provide disease control while minimizing long-term steroid exposure.

### The Growing Importance of Biomarkers and Personalized Medicine

As understanding of SLE pathophysiology deepens, the role of biomarkers in treatment selection and monitoring is expanding. Type I interferon signatures, complement levels, autoantibody profiles, and various cytokine patterns increasingly influence therapeutic decision-making.[23]

This trend toward personalized medicine is reshaping how rheumatologists and nephrologists approach treatment selection. Physicians are increasingly considering mechanism of action when making treatment decisions, particularly when choosing between targeted biologics with different mechanisms of action.

The days of one-size-fits-all treatment in lupus are fading as the field moves toward an era where pathway analysis and specific disease manifestations guide therapy selection. Manufacturers that clearly communicate how their products fit into this personalized approach will have a competitive advantage.

### Increased Focus on Lupus Nephritis

While SLE affects multiple organ systems, renal involvement through LN represents one of the most serious manifestations, associated with significant morbidity and mortality. Recognition of the severe impact of renal disease has led to increased focus on developing therapies specifically targeting LN.

Belimumab's and voclosporin's approvals for LN in 2020 and 2021, respectively, marked a significant milestone, offering the first targeted therapies specifically indicated for this complication.[1] This has been followed by increased clinical trial activity specifically examining renal outcomes in lupus patients. The successful Phase III trial (REGENCY) for obinutuzumab, a glyco-engineered anti-CD20 monoclonal antibody, should lead to FDA approval of this third targeted approach for LN in late 2025.[24]

Lupus nephritis represents an area of critical unmet need where new therapies can significantly impact patient outcomes. Companies demonstrating meaningful benefits in preserving renal function will find receptive audiences among both nephrologists and rheumatologists.

## Key Market Trends

### SLE Treatment Patterns

The vast majority of moderate-to-severe SLE patients rely on combination therapy to manage their disease. Hydroxychloroquine (HCQ) serves as the foundational agent for most SLE patients, with the 2023 updated EULAR guidelines recommending HCQ for all SLE patients unless contraindicated.[25,26]

Corticosteroids are utilized in approximately one-third of SLE patients without LN.[1,2] Nearly all rheumatologists acknowledge that steroid minimization is a key treatment goal in SLE management. In nearly half of cases, rheumatologists add a disease-modifying antirheumatic drug (methotrexate, MMF, or azathioprine) to the patient's regimen.[1,2]

Biologics (belimumab, anifrolumab, or rituximab) are utilized in about half of moderate-to-severe SLE patients.[1,2] Biologic use is typically reserved for patients who do not fully respond to conventional therapies or those who are reliant on corticosteroids. However, the 2023 EULAR guidelines upended this "add on" or "step" approach by acknowledging that biological agents could be added early in treatment, when appropriate.[25,26]

**LN Treatment Patterns**

For LN patients, HCQ remains a foundational agent, as it is essential for managing SLE in all patients diagnosed with LN. While there is no universally preferred DMARD for SLE, MMF is almost exclusively prescribed in LN and is considered the standard of care.[1,17]

Corticosteroids are prescribed more frequently in SLE patients with LN compared to those with nonrenal SLE due to the inherent severity of the condition. About half of LN patients rely on steroids to manage their disease. Similarly, about half of LN patients are prescribed an advanced systemic (biologic or calcineurin inhibitor) for their condition.[1,2]

Recent updates to lupus nephritis management have emerged through the 2024 American College of Rheumatology (ACR) LN guidelines, which introduced more nuanced treatment recommendations. These updated guidelines advocated for a three-pronged approach combining glucocorticoids with MMF or cyclophosphamide, plus either belimumab or a calcineurin inhibitor for patients experiencing new diagnoses, disease flares, or active Class III/IV ± V disease.[2]

The guidelines make an important distinction for patients with significant proteinuria (≥3 g/g), specifically recommending inclusion of a calcineurin inhibitor like voclosporin or tacrolimus in their treatment regimen.[20,21] This recommendation aligns with clinical reality—Spherix's comprehensive patient analysis revealed that a substantial majority of Class III/IV ± V LN patients presented with proteinuria levels above this threshold at initial diagnosis.[1,23]

For pure Class V disease, the ACR takes a different approach, suggesting CNI-containing triple therapy rather than belimumab-containing regimens when proteinuria reaches ≥1 g/g. This recommendation carries significant clinical relevance as Spherix data indicates most Class V patients already present with proteinuria exceeding this level at diagnosis.[1]

## Analyzing Success Factors in SLE/LN Product Launches

**Quantifying Market Performance**

A review of fifteen different drug launches between 2020 and 2021 provides valuable insights into what constitutes success in the SLE/LN market. This analysis compared estimated peak share projections to actual market share achieved three years post-launch.[1,2]

The findings reveal that products achieve approximately 30% of their prescriber projected peak market share by year three, on average. Standout performers demonstrate that exceeding this benchmark is possible with the right approach.




The analysis reveals belimumab's exceptional performance in the lupus nephritis space, where it captured 64% of its projected peak market share within just three years of approval. Anifrolumab demonstrated impressive results as well, achieving 45% of its projected peak share in the same timeframe. An important distinction emerges in their market entry strategies—belimumab's LN indication built on its established presence in the SLE market, while anifrolumab entered as a completely new biologic entity.

Looking across the broader analysis of fifteen product launches, only three outperformed anifrolumab's market penetration: belimumab in LN, upadacitinib in atopic dermatitis, and secukinumab in non-radiographic axial spondyloarthritis. Notably, these three standout performers all benefited from the strategic advantage of being line extensions from previously established therapies, highlighting the commercial value of leveraging existing brand recognition and prescriber familiarity.

## Case Study: Belimumab's Success in Lupus Nephritis

Belimumab's exceptional performance in LN provides a valuable case study in successful product positioning and launch execution. Several factors contributed to this success:

1. **Clear mechanistic rationale:** The B-cell modulating mechanism of action had a strong scientific basis for LN, supported by robust clinical data. Although the mechanism was not understood, data from the Phase III LN trial showed protection of GFR and reduction in renal flares.[17]
2. **Established presence:** GSK had already built relationships with rheumatologists through belimumab's use in nonrenal SLE, providing a foundation for expansion into nephrology. Rheumatologists were already familiar with the drug's profile and efficacy from over a decade of use in SLE, allowing for smoother adoption in the LN indication.[1] There was comfort in its safety data, particularly in terms of low risk of serious infection and no risk of malignancy.
3. **Targeted education:** GSK invested heavily in educating both rheumatologists and nephrologists about belimumab's role in managing LN, helping to bridge knowledge gaps between specialties.
4. **Supportive real-world evidence:** Post-approval data continued to reinforce belimumab's efficacy and safety profile, building confidence among prescribers.

This multifaceted approach enabled belimumab to outperform market expectations and establish itself as a key component of the LN treatment armamentarium.

**Differential Success Across Specialties**

While belimumab achieved remarkable success with rheumatologists, its adoption curve among nephrologists showed more modest growth, with this specialty achieving only 30% of the drug's projected peak market share by year three.[1] Interestingly, nephrologists demonstrate a more balanced perspective between belimumab and voclosporin, lacking the preference pattern seen among rheumatologists.

This pattern likely reflects nephrologists' extensive historical experience with calcineurin inhibitors, which they've utilized in transplantation medicine since the 1980s. This decades-long familiarity has established a comfort level with the drug class that rheumatologists simply haven't developed to date.[1,2] Such specialty-specific treatment preferences highlight the importance of tailored launch strategies that acknowledge different physician backgrounds when introducing therapies that cross specialty boundaries in the SLE/LN treatment space.

**Anifrolumab's Niche Strategy Success**

Anifrolumab, introduced by AstraZeneca specifically for SLE, demonstrated exceptional market penetration by achieving 45% of its projected peak share within just three years. Among the fifteen 2020-2021 product launches analyzed by Spherix, anifrolumab emerged as the most successful entirely new brand, with only line extension products outperforming peak share achievement.

This success stems from AstraZeneca's precision-targeted approach focusing on a specific SLE patient subset: those with prominent cutaneous manifestations, including malar rash, photosensitivity, alopecia, and specialized presentations like discoid lupus erythematosus (DLE) and subacute cutaneous lupus (SCLE).[24] This strategic positioning differentiated anifrolumab from other treatment options, including rituximab (available as both branded Rituxan and biosimilars), an anti-CD20 monoclonal antibody frequently prescribed off-label for both SLE and LN.

Spherix's comprehensive analysis of 1,017 moderate-to-severe SLE patients provides empirical validation for this strategic positioning. The data reveals that 56% of patients initiated on anifrolumab presented with moderate-to-severe cutaneous manifestations, significantly higher than the 39% observed with belimumab and 29% with rituximab.[1] Clinician assessments further reinforce this pattern, with rheumatologists consistently rating anifrolumab's efficacy for dermatological symptoms more favorably than belimumab's performance in this domain.

This targeted approach illustrates the value of identifying specific patient subpopulations where a therapy offers distinct advantages, rather than competing broadly across the entire disease spectrum. New market entrants should consider similar patient-centric segmentation strategies to maximize impact in this complex therapeutic landscape.

## Challenges and Barriers in the SLE/LN Market

Despite the opportunities presented by this evolving landscape, several significant challenges remain for companies seeking to launch products in the SLE/LN space:

### Diagnostic Delays and Disease Complexity

SLE remains challenging to diagnose, with some patients experiencing symptoms for years before receiving a definitive diagnosis. This diagnostic journey frequently involves multiple healthcare providers across different specialties.

By the time patients receive a definitive diagnosis, their disease may have already progressed significantly. Spherix's survey of 306 SLE patients revealed that 45% were not diagnosed with SLE until more than six months after first discussing their symptoms with a physician.[1]

Companies entering the market must account for this diagnostic complexity and consider how their products fit into treatment algorithms at different stages of the patient journey.

### Cross-Specialty Coordination

The management of SLE with renal involvement frequently necessitates coordination between rheumatologists and nephrologists, creating challenges in treatment consistency and clearly defined responsibilities.

The complexity extends beyond these two specialties, particularly for patients with cutaneous manifestations. Spherix data indicates that over half of SLE patients with concurrent cutaneous lupus erythematosus require co-management with dermatology.[1,2] This multispecialty involvement creates a more complex decision-making environment, with rheumatologists no longer serving as sole treatment arbiters for these patients. Additionally, specialty-specific preferences emerge in administration routes: rheumatologists typically demonstrate greater comfort with intravenous therapies, while dermatologists generally favor oral medication options.

Significant practice variation exists in lupus nephritis management protocols. Some medical centers maintain rheumatology-led care even after renal involvement develops, while others establish formal care transition protocols to nephrology. Successful product launches in this environment require sophisticated understanding of these cross-specialty dynamics and communication patterns.

**Payer Pressures and Access Challenges**

As more targeted therapies enter the market with premium pricing, payer scrutiny has intensified. Securing favorable formulary positioning and minimizing access barriers represents a significant challenge for new entrants.

Payer restrictions have a substantial impact on early product uptake. Products facing significant prior authorization requirements or step therapy mandates typically achieve lower market share in their initial years, regardless of clinical profile.

The access landscape for lupus therapies has become increasingly complex. Companies need comprehensive strategies that include robust patient support programs, clear value propositions for payers, and clinical data that specifically addresses cost-effectiveness considerations.

## Patient Perspective and Unmet Needs

Understanding disease patterns is crucial for both patients and physicians. Research shows that approximately 70% of SLE patients experience a relapsing-remitting disease course, while 10% have persistently active disease, and only 10% achieve prolonged remission.[8] This variability in disease patterns underscores the need for personalized treatment approaches.

**The Patient Journey**

The road to an SLE diagnosis is often lengthy and complex. In Spherix's patient research, many patients reported waiting one year or more after noticing symptoms before consulting a doctor, primarily because they did not believe their symptoms warranted medical attention. Even after discussing symptoms with a physician, one-third of SLE patients report that it took over a year to receive an accurate diagnosis, often due to multiple misdiagnoses.[1]

A majority of SLE patients express that they lacked but desired information on specific treatment types, lifestyle changes to help with their lupus, and how lupus impacts their other conditions.[1] This highlights a significant unmet need for patient education and support.

**Treatment Limitations and Gaps**

Current approved therapies for SLE and LN have demonstrated modest efficacy compared to placebo in clinical trials. For instance, in pivotal trials, belimumab plus standard therapy resulted in SRI-4 response rates that were only 9-14% higher than placebo plus standard therapy across various studies.[25] Similarly, in LN, the BLISS-LN trial showed that adding belimumab to standard therapy provided superior outcomes compared to placebo plus standard therapy, though the difference was only 11%.[17]

Rheumatologists report that 30% of their SLE patients on biologic therapy are not well-managed on their current regimen.[2] Additionally, physicians identify high unmet needs for new agents to treat steroid-dependent patients, those with frequent disease flares, and patients with cardiovascular involvement.

In LN, both nephrologists and rheumatologists cite high unmet needs for patients with elevated, persistent proteinuria, those who are steroid-dependent, and those with rapid GFR decline. The specialty-specific preferences for addressing these unmet needs vary, with nephrologists and rheumatologists often favoring different advanced therapies for specific patient subtypes.

## Strategies for Optimizing Product Performance

Based on extensive research and expert analysis, several key factors emerge as critical to successful product launches in the SLE/LN space:

**Deep Understanding of Disease Biology and Patient Heterogeneity**

SLE is characterized by remarkable heterogeneity in presentation, disease course, and treatment response. Companies that demonstrate a sophisticated understanding of this heterogeneity and can clearly articulate where their products fit within specific patient segments gain credibility with specialists.

Physicians are increasingly looking for guidance on which patients are most likely to benefit from specific therapies. Companies that can provide clear, evidence-based insights on patient selection will have an advantage in this complex landscape.

This understanding must be reflected not just in marketing materials but in clinical trial design, publication strategies, and medical education initiatives.

**Effective Cross-Specialty Engagement**

Given the collaborative care model that often characterizes SLE/LN management, effective engagement across rheumatology, nephrology, and other specialties, as needed, is essential. This requires nuanced messaging that resonates with specialists while acknowledging their different perspectives and priorities.

Successful companies develop specialized teams with expertise in both rheumatology and nephrology, ensuring consistent messaging while adapting to the unique needs of each specialty. Educational initiatives that bring both specialties together have proven particularly effective in building consensus around new treatment approaches.

**Comprehensive Support Beyond the Product**

The complexity of SLE/LN management extends beyond medication selection to encompass diagnosis, monitoring, and long-term disease management. Companies that provide comprehensive support programs addressing these broader needs can differentiate themselves in a competitive market.

Such support may include diagnostic tools, monitoring programs, patient education resources, and initiatives to improve care coordination between specialties. These value-added services demonstrate commitment to improving overall patient outcomes, not just promoting product usage.

**Clear Differentiation in a Growing Market**

As the number of treatment options increases, clear differentiation becomes increasingly important. Companies must articulate how their products offer unique benefits compared to existing options, whether through novel mechanisms of action, improved efficacy in specific disease manifestations, enhanced safety profiles, or more convenient administration.

The days of simply being “another option” in lupus are gone. Each new entrant needs to clearly communicate what makes their product unique and which patients are most likely to benefit from their specific approach.

## Pipeline and Future Outlook

The pipeline for SLE/LN treatments remains robust, with multiple mechanisms of action under investigation. Novel approaches targeting type I interferons, various interleukins, B cells, T cells, TLR7/8, CD40L, plasmacytoid dendritic cells, and other components of the immune system implicated in lupus pathogenesis are in development.

Several late-stage pipeline agents show promise for SLE, including litifilimab (Biogen), an IgG1 monoclonal antibody against BDCA2; obinutuzumab (Roche/Genentech), a type II humanized anti-CD20 monoclonal antibody; deucravacitinib (BMS), a TYK2 inhibitor; cenerimod (Idorsia/Viatris), a selective sphingosine-1-phosphate receptor 1 modulator; and several other promising candidates.

For LN specifically, obinutuzumab has shown positive results in its Phase III REGENCY clinical trial. Roche has filed for FDA and EMA approval, with decisions anticipated before the end of 2025. Specialists indicate that approximately one-quarter of their Class III/IV ± V LN patients would be candidates for this biologic.[1,2] All the new therapies for LN (belimumab, voclosporin, obinutuzumab) have complete renal response rates that plateau in the 40% range, so there is a need for additional therapeutic advances.[17,18,20]

Beyond traditional biologics and small molecules, cell therapies represent an emerging frontier in lupus treatment, with more than ten cell therapies currently in development. Approximately half of specialists believe CAR T-cell therapy could play a key role in SLE treatment if approved, potentially offering the closest thing to a “cure” for a subset of patients, though concerns about excessive costs and safety remain.[1,2]

**New Approaches in SLE/LN Treatment**

The SLE/LN landscape continues to evolve rapidly, with several emerging trends likely to shape the market in coming years:

**Expanding Biologic Options**

As the pipeline matures, the treatment paradigm will likely evolve toward more personalized approaches based on specific disease manifestations, biomarker profiles, and patient characteristics.

**Combination Approaches Gaining Traction**

Given the complex pathophysiology of SLE, combination approaches targeting multiple pathways simultaneously show increasing promise. Early research suggests that such combinations may offer synergistic benefits while potentially allowing for lower doses of individual agents.

There is growing interest in strategic combinations that address multiple aspects of lupus pathophysiology. Companies that can demonstrate how their products complement existing therapies may find opportunities even in an increasingly crowded market.

**Increased Focus on Long-Term Outcomes**

As treatment options expand, attention is shifting toward long-term outcomes beyond immediate disease control, including preservation of organ function, prevention of damage accrual, reduction in steroid exposure, and improvements in quality of life. Companies that generate compelling data on these outcomes will be well-positioned to demonstrate value to clinicians and payers.

## The Path Forward for Stakeholders in SLE/LN

The SLE/LN landscape presents significant opportunities and challenges for pharmaceutical companies, healthcare providers, and patients. Success requires deep clinical understanding, sophisticated stakeholder engagement, and tailored strategies unique to this disease space.

Comprehensive analysis of market trends and launch performance provides valuable guidance for navigating this evolving landscape. The data demonstrates that success requires specialized knowledge and strategic approaches addressing the unique challenges of the SLE/LN market.

The companies that will succeed in this space are those that develop a profound understanding of clinical nuances, physician perspectives, and patient needs that drive treatment decisions. This understanding, combined with clear differentiation and comprehensive support programs, forms the foundation for successful product launches in this challenging therapeutic area.

**References**


1. Patient Chart Dynamix™: SLE (US). 2025. [unavailable online]
2. Market Dynamix™: Lupus (SLE/LN) (US). 2023. [unavailable online]
3. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on Lupus Nephritis: Core Curriculum 2020. Am J Kidney Dis. 2020;76(2):265-281. Available from: https://pubmed.ncbi.nlm.nih.gov/32220510/.
4. Lupus Foundation of America. Lupus facts and statistics. Accessed September 16, 2025. Available from: https://www.lupus.org/resources/lupus-facts-and-statistics.

5. Kamen DL. Environmental influences on systemic lupus erythematosus expression. Rheum Dis Clin North Am. 2014;40(3):401-412. Available from: https://pubmed.ncbi.nlm.nih.gov/25034153/.

6. Ceccarelli F, Perricone C, et al. Genetic factors in systemic lupus erythematosus: contribution to disease phenotype. J Immunol Res. 2015;2015:745647. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699011/.

7. Rees F, Doherty M, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017;56(11):1945-1961. Available from: https://academic.oup.com/rheumatology/article/56/11/1945/4079913.

8. Tselios K, Gladman DD, et al. Disease course patterns in systemic lupus erythematosus. Lupus. 2019;28(1):114-122. Available from: https://journals.sagepub.com/doi/10.1177/0961203318817132.

9. Aringer M, Costenbader K, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151-1159. Available from: https://pubmed.ncbi.nlm.nih.gov/31385462/.

10. Barber MRW, Drenkard C, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(9):515-532. Available from: https://www.nature.com/articles/s41584-021-00668-1.

11. Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (Oxford). 2020;59(Suppl 5):v29-v38. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719040/.

12. Lim SS, Bayakly AR, et al. The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry. Arthritis Rheumatol. 2014;66(2):357-368. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226684/.

13. Hasan B, Fike A, Hasni S. Health disparities in systemic lupus erythematosus—a narrative review. Lupus. 2021;30(14):2191-2207. Available from: https://link.springer.com/article/10.1007/s10067-022-06268-y#:~:text=They%20found%20that%20South%20Asian,in%20this%20study%20%5B84%5D.

14. Lupus Foundation of America. Prognosis and life expectancy. Accessed September 16, 2025. Available from: https://www.lupus.org/resources/prognosis-and-life-expectancy.

15. Rúa-Figueroa Í, López-Longo J, et al.; RELESSER-EULAR group. National registry of patients with systemic lupus erythematosus of the Spanish Society of Rheumatology: objectives and methodology. Reumatol Clin. 2016;12(1):13-21. Available from: https://pubmed.ncbi.nlm.nih.gov/23871155/

16. Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (Oxford). 2020;59(Suppl 5):v29-v38. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719040/.

17. Furie R, Rovin BH, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2001180.

18. Navarra SV, Guzmán RM, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731. Available from: https://pubmed.ncbi.nlm.nih.gov/21296403/

19. Rovin BH, Teng YKO, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070-2080. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00578-X/fulltext.

20. Furie R, Khamashta M, et al; CD1013 Study Investigators. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376-386. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299497/.

21. Weeding E, Fava A, et al. One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria. Lupus Sci Med. 2022;9(1):e000684. Available from: https://lupus.bmj.com/content/9/1/e000684.

22. Fanouriakis A, Kostopoulou M, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. Available from: https://ard.bmj.com/content/83/1/15.

23. Fanouriakis A, Kostopoulou M, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. Available from: https://ard.bmj.com/content/78/6/736.

24. Carter LM, Wigston Z, et al. Rapid efficacy of anifrolumab across subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. Presented at: American College of Rheumatology Convergence 2023; November 10-14, 2023; San Diego, CA. Available from: https://pubmed.ncbi.nlm.nih.gov/36944572/.

25. Furie RA, Petri MA, et all. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143-1151. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.24698.